6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Eidos Therapeutics, Inc.

101 Montgomery Street
Suite 2550
San Francisco, CA 94101
United States

Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Dr. Neil KumarCEO & Director823.15kN/A1979
Dr. Isabella Graef M.D.Founder & Board Advisor150kN/A1965
Dr. Uma SinhaChief Scientific Officer & Director3.3MN/A1957
Dr. Cameron TurtleChief Bus. Officer2.1MN/A1990
Dr. Hoyoung HuhConsultant19.3kN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

Corporate Governance

Eidos Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.